Celaid Therapeutics Inc.

About Celaid Therapeutics Inc.

Celaid Therapeutics aims to develop new cell therapies using hematopoietic stem cells (HSCs) for blood cancers such as leukemia, intractable blood disorders, and genetic diseases. Their mission is to change the future with innovative cell therapy solutions by leveraging cutting-edge technology to apply HSCs in clinical settings.

Products & Services

Next-Generation Cell Therapy Products:Development of cell therapy products using hematopoietic stem cells from umbilical cord blood and peripheral blood, amplified in large quantities to treat blood cancers and genetic diseases.

Ex Vivo HSC Amplification Technology:A technology for mass proliferation of functional hematopoietic stem cells with blood reconstitution capabilities, produced at high quality and low cost without animal-derived components.

Specialties

Hematopoietic Stem Cell Therapy Cell Therapy for Blood Cancers Genetic Disease Treatment Ex Vivo Cell Amplification Technology Regenerative Medicine

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 7200000 MR: - FA: JPY 1.055 billion FAN: 7200000	D: 2025-10-07 FD: 2025-10-07	5 investors

Series B Latest

2025-10-07

$7.2M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

N

Nobuyuki Arakawa

Co-founder / Representative Director, President and CEO

Y

Yusuke Inoue

Director, COO & CFO

A

Asako Uchiyama

Board Director, Chief Development Officer and Head of Product Development Department

A

Atsushi Usami

Outside Director

Y

Yuki Taga

Outside Director

A

Azusa Shiohara

Outside Auditor

View 19 more team members with Pro

Unlock Full Team Directory

Recent News